213 related articles for article (PubMed ID: 26132001)
1. Glycosylation Analysis for Congenital Disorders of Glycosylation.
Li X; Raihan MA; Reynoso FJ; He M
Curr Protoc Hum Genet; 2015 Jul; 86():17.18.1-17.18.22. PubMed ID: 26132001
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry of transferrin glycoforms to detect congenital disorders of glycosylation: Site-specific profiles and pitfalls.
Wada Y
Proteomics; 2016 Dec; 16(24):3105-3110. PubMed ID: 27095603
[TBL] [Abstract][Full Text] [Related]
3. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG.
Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L
J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691
[TBL] [Abstract][Full Text] [Related]
4. MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis.
Yen-Nicolaÿ S; Boursier C; Rio M; Lefeber DJ; Pilon A; Seta N; Bruneel A
Proteomics Clin Appl; 2015 Aug; 9(7-8):787-93. PubMed ID: 25641685
[TBL] [Abstract][Full Text] [Related]
5. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation.
Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M
Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051
[TBL] [Abstract][Full Text] [Related]
6. Increased Clinical Sensitivity and Specificity of Plasma Protein
Chen J; Li X; Edmondson A; Meyers GD; Izumi K; Ackermann AM; Morava E; Ficicioglu C; Bennett MJ; He M
Clin Chem; 2019 May; 65(5):653-663. PubMed ID: 30770376
[TBL] [Abstract][Full Text] [Related]
7. A Novel N-Tetrasaccharide in Patients with Congenital Disorders of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies.
Zhang W; James PM; Ng BG; Li X; Xia B; Rong J; Asif G; Raymond K; Jones MA; Hegde M; Ju T; Cummings RD; Clarkson K; Wood T; Boerkoel CF; Freeze HH; He M
Clin Chem; 2016 Jan; 62(1):208-17. PubMed ID: 26430078
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry for congenital disorders of glycosylation, CDG.
Wada Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 838(1):3-8. PubMed ID: 16517226
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical characterization of a patient with congenital disorder of glycosylation (CDG) IIx.
Miura Y; Tay SK; Aw MM; Eklund EA; Freeze HH
J Pediatr; 2005 Dec; 147(6):851-3. PubMed ID: 16356446
[TBL] [Abstract][Full Text] [Related]
10. ALG12-CDG: novel glycophenotype insights endorse the molecular defect.
Sturiale L; Bianca S; Garozzo D; Terracciano A; Agolini E; Messina A; Palmigiano A; Esposito F; Barone C; Novelli A; Fiumara A; Jaeken J; Barone R
Glycoconj J; 2019 Dec; 36(6):461-472. PubMed ID: 31529350
[TBL] [Abstract][Full Text] [Related]
11. Insights into complexity of congenital disorders of glycosylation.
Goreta SS; Dabelic S; Dumic J
Biochem Med (Zagreb); 2012; 22(2):156-70. PubMed ID: 22838182
[TBL] [Abstract][Full Text] [Related]
12. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.
Sturiale L; Barone R; Garozzo D
J Inherit Metab Dis; 2011 Aug; 34(4):891-9. PubMed ID: 21384227
[TBL] [Abstract][Full Text] [Related]
13. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG).
Casetta B; Malvagia S; Funghini S; Martinelli D; Dionisi-Vici C; Barone R; Fiumara A; Donati MA; Guerrini R; la Marca G
Clin Chem Lab Med; 2020 Aug; 59(1):165-171. PubMed ID: 32776892
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of glycation and glycation sites of lysozyme by matrix-assisted laser desorption/ionization time of flight/time-of-flight mass spectrometry and Liquid chromatography-electrospray ionization tandem mass spectrometry.
Ruan ED; Wang H; Ruan Y; Juáreza M
Eur J Mass Spectrom (Chichester); 2014; 20(4):327-36. PubMed ID: 25420345
[TBL] [Abstract][Full Text] [Related]
15. A new method for the rapid diagnosis of protein N-linked congenital disorders of glycosylation.
Heywood WE; Mills P; Grunewald S; Worthington V; Jaeken J; Carreno G; Lemonde H; Clayton PT; Mills K
J Proteome Res; 2013 Jul; 12(7):3471-9. PubMed ID: 23742123
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of congenital disorders of glycosylation type I by analysis of transferrin glycoforms.
Babovic-Vuksanovic D; O'Brien JF
Mol Diagn Ther; 2007; 11(5):303-11. PubMed ID: 17963418
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation.
Wada Y; Okamoto N
J Mass Spectrom; 2021 Apr; 56(4):e4597. PubMed ID: 32677746
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation.
Wada Y
Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821
[TBL] [Abstract][Full Text] [Related]
19. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II.
Guillard M; Morava E; van Delft FL; Hague R; Körner C; Adamowicz M; Wevers RA; Lefeber DJ
Clin Chem; 2011 Apr; 57(4):593-602. PubMed ID: 21273509
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis.
Papazoglu GM; Cubilla M; Pereyra M; de Kremer RD; Pérez B; Sturiale L; Asteggiano CG
Glycoconj J; 2021 Apr; 38(2):191-200. PubMed ID: 33644825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
